In a small cohort of 7 ALK-positive NSCLC, the monitoring of the different ALK resistance mutations status during the course of the disease was successfully performed [71] but further and wider studies are required to assess the ddPCR clinical utility to detect ALK secondary mutations and their implication in patients PFS and OS. Here, ALK is linked to non-small cell lung carcinoma.